Specifically, the ELIXA (lixisenatide) trial studied patients with T2DM who had recent acute coronary syndrome and found that the addition of lixisenatide to conventional therapy did not result in a significant difference in cardiovascular endpoints relative to placebo (Table 1) [56]
Lilly's triple agonist retatrutide demonstrated significant A1C and weight reductions in Phase 3 type 2 diabetes trial Eli Lilly and Company Phase 3 programme The evidence base, in numbers Phase 3 trials registered 14 Completed 5 Results disclosed by Lilly 5 Peer-reviewed publications 1 Four of the five disclosed readouts are topline results reported by Lilly and have not yet been fully evaluated in a peer-reviewed publication
Whether you're navigating a GLP-1 diet, curious about foods to prioritize vs
PubMed 12750433 Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK
examines how corporate, multiemployer and public employers are addressing coverage and policy decisions related to GLP-1 medications, traditionally used for diabetes management and weight loss